Previous Grants

The following grants were approved prior to July 2016

Project Grant


Dr Megan Wilson University of Otago 2015 December

Sex-dimorphic brain development and disease: the role a non-coding RNA encoded within the Anti-Müllerian hormone locus

Shedding light on the nature of neurodevelopmental disorders depending upon the sex of the child

Susceptibility to many common neurological and psychiatric conditions differs and shows a dramatic sex basis – whether the person is male or female. Formation of the human brain during foetal development follows a slightly different path depending upon the sex of the child. These differences arise even before sex-hormones are produced. By determining how male and female sex impacts on the developing brain we hope to shed light on the nature of how sex differences to neurodevelopmental disorders arise.


Nid: 1410

Neurological Foundation Gillespie Postgraduate Scholarship


Ruth Monk University of Auckland 2015 December

Modelling Huntington’s Disease: Using direct cell reprogramming to study the mechanisms underlying a complex genetic neurodegenerative disorder

Creating a model of Huntington’s disease from patient skin cells to further understand the underlying mechanisms and cell death involved in this disorder

Huntington’s Disease (HD) is a highly debilitating genetic neurodegenerative disorder which is characterised by the progressive loss of specific brain cells. What drives this specific cell loss remains largely unknown, and consequently there is no treatment for this disease. Ms Monk’s project aims to generate a model of HD by reprogramming skin cells from patients into the specific brain cell type lost in this condition. This model will provide a novel platform for elucidating the complex mechanisms contributing to brain cell death, and will play an important role in the development of treatments for HD.

Nid: 1400

Summer Studentship


Niamh Hammond University of Otago, Wellington 2015 December

Recent onset transient or episodic headaches with concerning features: risk prediction, pre-test probability, and imaging selection

Differentiating patients with headache to identify serious and life-threatening brain bleeds 

Episodic headaches are a widely experienced complaint. While the majority are due to benign processes, some headaches can herald serious and life‐threatening diseases. One such cause is a type of brain bleed known as a subarachnoid haemorrhage that can present initially as a ‘sentinel bleed’. This research aims to investigate the proportion of patients presenting with transient headache and concerning features that are later confirmed to have these serious brain bleeds. This information will help to identify these patients so that they receive the appropriate scans and treatment in a timely fashion that reduces potential serious illness.

Nid: 1411

Neurological Foundation W & B Miller Postgraduate Scholarship


Molly Swanson University of Auckland 2015 December

Investigating inflammation in the Alzheimer’s Disease Olfactory Bulb

Investigating early inflammatory changes and their influences in the progression of Alzheimer’s Disease

While the most widely known symptom of Alzheimer’s disease (AD) is short term memory loss, one of the earliest symptoms is often a loss of the sense of smell. This symptom, known as anosmia, is thought to be due to olfactory neuron degeneration or insufficient replacement of olfactory neurons throughout life. Ms Swanson’s research will test the hypothesis that AD pathology is triggered by inflammatory processes in the olfactory bulb by studying post-mortem human brain tissue from the Neurological Foundation Human Brain Bank and using cultured cells. Ultimately, this research will provide insight into early changes occurring in the AD brain which will aid early detection and therapeutic intervention.

Nid: 1401

Summer Studentship


Olufolakemi (Kemi) Bolarinwa University of Otago 2015 December

Does sAPPα give neuroprotection through its interaction with BACE 1, the enzyme involved in the production of the neurotoxic amyloid β peptide?

Can the interaction of proteins involved in Alzheimer’s disease produce a protective factor?    

Late onset Alzheimer’s disease is a growing social and economic burden worldwide and in New Zealand. As yet there are no effective therapies or early intervention treatments. Small soluble aggregates of a peptide are believed to be the toxic species that destroys neurons and impairs memory in Alzheimer’s disease. This peptide is processed from the same large protein as another protein that by contrast restores memory. This neuroprotective protein may bind and inhibit the enzyme that produces the toxic peptide. This project will explore this interaction for the potential of the development of a therapeutic agent or treatment.

Nid: 1412